Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
|
|
USA Today (10.28.09) - Wednesday, October 28, 2009
Rita Rubin
In the study, 89,784 Dutch women were randomized to be screened either with ThinPrep or a conventional Pap smear. After evaluating the data, the authors concluded that "liquid- based cytology does not perform better than conventional Pap tests in terms of relative sensitivity and [positive predictive value] for detection of cervical cancer precursors."
Pap smear testing has been in use since the 1940s, while ThinPrep received US approval in 1996. The main difference between the two tests is how the cells are prepared for evaluation. The Food and Drug Administration has allowed ThinPrep's maker, Hologic, to promote the test as being more effective at revealing early and more advanced abnormalities in the cervix.
ThinPrep, while more expensive, "is preferred by most laboratories because the specimen is easier and quicker to scan under the microscope," said an accompanying editorial by Mark Schiffman and Diane Solomon.
Many doctors were forced to switch to the test when labs stopped reading Pap smears, said George Sawaya, an obstetrician/gynecologist at the University of California-San Francisco. The results of the new study "should serve as a cautionary tale that just because something is new doesn't mean it's better," he said.
Lead author Albertus G. Siebers, MSc, said other factors to consider include the ability to use ThinPrep samples to test for human papillomavirus - the STD that causes nearly all cases of cervical cancer - and the fact that only one in 300 ThinPrep tests had to be redone, versus one in 100 Pap tests.
The report, "Comparison of Liquid-Based Cytology with Conventional Cytology for Detection of Cervical Cancer Precursors," and the editorial, "Screening and Prevention Methods for Cervical Cancer," were published in the Journal of the American Medical Association (2009;302(16):1757-1764,1809- 1810).
091028
AD091852
Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.